Mederacke, IngmarYurdaydın, CihanDalekos, George N.Bremer, BirgitErhardt, AndreasÇakaloğlu, YılmazYalçın, KendalZeuzem, StefanZachou, KalliopiBozkaya, HakanDienes, Hans PeterManns, Michael P.Wedemeyer, Heiner2022-04-012022-04-012012Mederacke, I. vd. (2012). "Anti-HDV immunoglobulin M testing in hepatitis delta revisited: Correlations with disease activity and response to pegylated interferon-alpha 2a treatment". Antiviral Therapy, 17(2), 305-312.1359-6535https://doi.org/10.3851/IMP1926http://hdl.handle.net/11452/25531Background: The role of anti-HDV immunoglobulin M (IgM) testing in patients receiving pegylated interferon-alpha therapy for hepatitis delta is unknown. We performed anti-HDV IgM testing in a well defined cohort of HDVinfected patients who were treated with pegylated interferon-alpha 2a plus adefovir, or either drug alone. Methods: Sera from 33 HDV-RNA-positive patients from the international HIDIT-1 trial were available for anti-HDV IgM testing (ETI-DELTA-IGMK-2 assay, DiaSorin, Saluggia, Italy) before therapy, at treatment weeks 24 and 48, and at 24 weeks after the end of treatment. Results: Anti-HDV IgM tested positive in 31 out of the 33 patients (94%) prior to treatment. HDV IgM levels correlated with histological inflammatory activity (r= 0.51, P<0.01) and were higher in patients with alanine aminotransferase and gamma-glutamyl transpeptidase levels above the median (P<0.05). Quantitative anti-HDV IgM values declined in patients responding to antiviral therapy, however anti-HDV IgM remained positive after treatment in the majority of virological responders. Conclusions: We suggest that anti-HDV IgM testing might give additional useful information to determine disease activity in hepatitis delta and to predict treatment response to antiviral therapy with type I interferons. However, determination of anti-HDV IgM can not substitute HDV RNA testing, which remains the primary virological marker for response to therapy.eninfo:eu-repo/semantics/closedAccessInfectious diseasesPharmacology & pharmacyVirologyT-cell responseVirus-infectionIgm antibodiesI-interferonPatternsTherapyEuropeSerumRnaHbvAdenineAdultAlanine transaminaseAntiviral agentsFemaleGamma-glutamyltransferaseHepatitis antibodiesHepatitis dHepatitis delta virusHumansImmunoglobulin mInterferon-alphaMaleMiddle agedPhosphonic acidsPolyethylene glycolsRecombinant proteinsRna, viralYoung adultArticle0003039872000062-s2.0-8486032666530531217222293066Infectious diseasesPharmacology & pharmacyVirologyHepatitis Delta Virus; Chronic Hepatitis D; LonafarnibAdefovirAlanine aminotransferaseGamma glutamyltransferaseImmunoglobulin m antibodyPeginterferon alpha2aPlaceboVirus dnaVirus rnaAdultAlanine aminotransferase blood levelAnalytical equipmentAntibody detectionAntibody titerAntiviral therapyClinical articleCohort analysisControlled studyDelta agent hepatitisDisease activityDisease associationFemaleGamma glutamyl transferase blood levelHumanHuman tissueImmunoglobulin blood levelInflammationMaleMulticenter study (topic)Priority journalRandomized controlled trial (topic)ReviewTreatment durationTreatment responseVirus load